Carcinogenesis, Vol. 22, No. 4, 559-565,
April 2001
© 2001 Oxford University Press
CANCER BIOLOGY |
Se-Methylselenocysteine induces apoptosis through caspase activation in HL-60 cells
Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Taejon 305-701, Korea
Apoptosis, a programmed process of cell suicide, has been proposed as the most plausible mechanism for the chemopreventive activities of selenocompounds. In our study, we found that Se-methylselenocysteine (MSC) induced apoptosis through caspase activation in human promyelocytic leukemia (HL-60) cells. Measurements of cytotoxicity, DNA fragmentation and apoptotic morphology revealed that MSC was more efficient at inducing apoptosis than selenite, but was less toxic. Moreover, MSC increased both the apoptotic cleavage of poly(ADP-ribose) polymerase (PARP) and caspase-3 activity, whereas selenite did not. We next examined whether caspases and serine proteases are required for the apoptotic induction by MSC. A general caspase inhibitor, z-VAD-fmk, dramatically decreased cytotoxicity in MSC-treated HL-60 cells and several other apoptotic features, such as, caspase-3 activation, the apoptotic DNA ladder, TUNEL-positive staining and the DNA double-strand break. Interestingly, a general serine protease inhibitor, AAPV-cmk, also effectively inhibited MSC-mediated cytotoxicity and apoptosis. These results demonstrate that MSC is a selenocompound that efficiently induces apoptosis in leukemia cells and that proteolytic machinery, in particular caspase-3, is necessary for MSC-induced apoptosis. On the other hand, selenite-induced cell death could be derived from necrosis rather than apoptosis, since selenite did not significantly induce several apoptotic phenomena, including the activation of caspase-3.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G.-x. Li, H.-J. Lee, Z. Wang, H. Hu, J. D. Liao, J. C. Watts, G. F. Combs Jr, and J. Lu Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite Carcinogenesis, May 1, 2008; 29(5): 1005 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhang, X. Wang, and T. Xu Elemental Selenium at Nano Size (Nano-Se) as a Potential Chemopreventive Agent with Reduced Risk of Selenium Toxicity: Comparison with Se-Methylselenocysteine in Mice Toxicol. Sci., January 1, 2008; 101(1): 22 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bulucu, C. Oktenli, L. Kenar, B. Koc, R. Ocal, N. Karadurmus, V. Inal, L. Yamanel, Y. S. Sanisoglu, and A. Aydin Detrimental Effects of N-Acetylcysteine Plus Desferoxamine Combination in an Experimental Nephrotic Syndrome Model International Journal of Toxicology, November 1, 2007; 26(6): 525 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Azrak, C. L. Frank, X. Ling, H. K. Slocum, F. Li, B. A. Foster, and Y. M. Rustum The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells. Mol. Cancer Ther., October 1, 2006; 5(10): 2540 - 2548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hu, C. Jiang, T. Schuster, G.-X. Li, P. T. Daniel, and J. Lu Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway. Mol. Cancer Ther., July 1, 2006; 5(7): 1873 - 1882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Azrak, J. Yu, L. Pendyala, P. F. Smith, S. Cao, X. Li, W. D. Shannon, F. A. Durrani, H. L. McLeod, and Y. M. Rustum Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors Mol. Cancer Ther., May 1, 2005; 4(5): 843 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jiang, H. Hu, B. Malewicz, Z. Wang, and J. Lu Selenite-induced p53 Ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells Mol. Cancer Ther., July 1, 2004; 3(7): 877 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. V. Gopee, V. J. Johnson, and R. P. Sharma Sodium Selenite-Induced Apoptosis in Murine B-Lymphoma Cells Is Associated with Inhibition of Protein Kinase C-{delta}, Nuclear Factor {kappa}B, and Inhibitor of Apoptosis Protein Toxicol. Sci., April 1, 2004; 78(2): 204 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cao, F. A. Durrani, and Y. M. Rustum Selective Modulation of the Therapeutic Efficacy of Anticancer Drugs by Selenium Containing Compounds against Human Tumor Xenografts Clin. Cancer Res., April 1, 2004; 10(7): 2561 - 2569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-y. Wang Ham-Wasserman Lecture: Treatment of Acute Leukemia by Inducing Differentiation and Apoptosis Hematology, January 1, 2003; 2003(1): 1 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jiang, Z. Wang, H. Ganther, and J. Lu Distinct Effects of Methylseleninic Acid versus Selenite on Apoptosis, Cell Cycle, and Protein Kinase Pathways in DU145 Human Prostate Cancer Cells Mol. Cancer Ther., October 1, 2002; 1(12): 1059 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rooseboom, G. Schaaf, J. N. M. Commandeur, N. P. E. Vermeulen, and J. Fink-Gremmels beta -Lyase-Dependent Attenuation of Cisplatin-Mediated Toxicity by Selenocysteine Se-Conjugates in Renal Tubular Cell Lines J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 884 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zeng Selenite and Selenomethionine Promote HL-60 Cell Cycle Progression J. Nutr., April 1, 2002; 132(4): 674 - 679. [Abstract] [Full Text] [PDF]
|
|